Rossari Biotech Limited — Important, 21-01-2025: Updates

The Board of Directors of Rossari Biotech Limited has approved the unaudited financial results for the quarter and nine months ended December 31, 2024. Key highlights include revenue from operations of ₹3,682.78 million for the quarter, showing a healthy year-on-year growth from ₹2,987.52 million. The profit after tax for the period stands at ₹306.31 million, compared to ₹255.42 million in the same period last year. Cost management remains robust, with total expenses amounting to ₹3,280.22 million.

In a strategic move, the company is shifting its registered office within Mumbai, effective February 1, 2025. Furthermore, the Board has allotted 7,500 equity shares under the Rossari Employee Stock Option Plan – 2019, increasing the paid-up equity share capital to ₹1,107.27 million. Additionally, M/s. Shah Patel & Associates has been appointed as the Secretarial Auditor for the financial year 2024-25, enhancing governance structures within the firm. The outlook remains positive, underscored by growing operational capacity and market expansion efforts.